IMFINZI study in patients with extensive stage small cell lung cancer

Study identifier:D419QC00006

ClinicalTrials.gov identifier:NCT04854590

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

IMFINZI® Injection 120 mg, 500 mg Specific-Clinical Experience Investigation in patients with extensive stage small cell lung cancer

Medical condition

Carcinoma, Small Cell

Phase

N/A

Healthy volunteers

No

Study drug

-

Sex

All

Actual Enrollment

248

Study type

Observational

Age

n/a - n/a

Date

Study Start Date: 22 Apr 2021
Primary Completion Date: 25 Jul 2023
Study Completion Date: 25 Jul 2023

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Jul 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria